Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
128.11
-0.04 (-0.03%)
At close: Jun 27, 2025, 4:00 PM
128.07
-0.04 (-0.03%)
After-hours: Jun 27, 2025, 7:00 PM EDT
Blueprint Medicines Employees
Blueprint Medicines had 649 employees as of December 31, 2024. The number of employees decreased by 6 or -0.92% compared to the previous year.
Employees
649
Change (1Y)
-6
Growth (1Y)
-0.92%
Revenue / Employee
$866,134
Profits / Employee
-$239,952
Market Cap
8.29B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 649 | -6 | -0.92% |
Dec 31, 2023 | 655 | 14 | 2.18% |
Dec 31, 2022 | 641 | 146 | 29.49% |
Dec 31, 2021 | 495 | 66 | 15.38% |
Dec 31, 2020 | 429 | 46 | 12.01% |
Dec 31, 2019 | 383 | 166 | 76.50% |
Dec 31, 2018 | 217 | 68 | 45.64% |
Dec 31, 2017 | 149 | 43 | 40.57% |
Dec 31, 2016 | 106 | 25 | 30.86% |
Dec 31, 2015 | 81 | 20 | 32.79% |
Dec 31, 2014 | 61 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BPMC News
- 7 days ago - BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC - Business Wire
- 15 days ago - Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - PRNewsWire
- 25 days ago - Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines - GlobeNewsWire
- 26 days ago - Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. - Barrons
- 26 days ago - Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology - PRNewsWire
- 26 days ago - Sanofi buys US biopharma group Blueprint in $9.1 bln deal - Reuters
- 26 days ago - Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion - WSJ
- 26 days ago - Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology - GlobeNewsWire